engineered human fusion constructs targeting CD33 and CEA antigens (MD Anderson Cancer Center/Clayton Foundation for Research)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Nameengineered human fusion constructs targeting CD33 and CEA antigens (MD Anderson Cancer Center/Clayton Foundation for Research)
Drug Alias NameGrB-Fc-CEAGrB-Fc-HU33
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Antigen
Mechanisms of ActionMyeloid cell surface antigen CD33 modulatorsCarcinoembryonic antigen related cell adhesion molecule 5 modulators
TargetsCarcinoembryonic antigen related cell adhesion molecule 5Myeloid cell surface antigen CD33
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesClayton Foundation For ResearchThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A